Literature DB >> 9614102

The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells.

C Lavagna-Sévenier1, S Marchetto, D Birnbaum, O Rosnet.   

Abstract

The FLT3 receptor tyrosine kinase and its ligand, FL, play an important role in early hematopoietic development. We have found that CBLB, a recently characterized molecule closely related to the CBL protooncogene product, is phosphorylated on tyrosine(s) following FL treatment of JEA2 human pro-B cells and THP1 monocytic cells. Treatment of JEA2 cells with interleukin (IL)-7 induces CBLB phosphorylation as well. FL and IL-7, respectively, induce and increase association of tyrosine-phosphorylated SHC and the p85 subunit of phosphatidylinositol 3'-kinase with CBLB. In these cells, CBLB constitutively binds the GRB2 adaptor predominantly through its N-terminal SH3 domain, to form a complex that is distinct from the GRB2.CBL and GRB2.SOS1 complexes. Together with the fact that CBLB is consistently found in blast cells from acute leukemias and in peripheral blood mononuclear cells, this suggests that CBLB has a role in tyrosine kinase-regulated signaling pathways in many hematolymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9614102     DOI: 10.1074/jbc.273.24.14962

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Treatment of FLT3-ITD acute myeloid leukemia.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Am J Blood Res       Date:  2011-09-09

2.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Authors:  Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-04       Impact factor: 11.205

Review 3.  Signal transduction of oncogenic Flt3.

Authors:  Chunaram Choudhary; Carsten Müller-Tidow; Wolfgang E Berdel; Hubert Serve
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

4.  FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Authors:  Amir T Fathi; Bruce A Chabner
Journal:  Oncologist       Date:  2011-07-17

Review 5.  Bench to bedside targeting of FLT3 in acute leukemia.

Authors:  Keith W Pratz; Mark J Levis
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

6.  FLT3/ITD AML and the law of unintended consequences.

Authors:  Mark Levis
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

Review 7.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

8.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

9.  qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL.

Authors:  Jana Fassunke; Marie-Christine Blum; Hans-Ulrich Schildhaus; Marc Zapatka; Benedikt Brors; Helen Künstlinger; Reinhard Büttner; Eva Wardelmann; Sabine Merkelbach-Bruse
Journal:  BMC Mol Biol       Date:  2010-12-20       Impact factor: 2.946

10.  Further activation of FLT3 mutants by FLT3 ligand.

Authors:  R Zheng; E Bailey; B Nguyen; X Yang; O Piloto; M Levis; D Small
Journal:  Oncogene       Date:  2011-04-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.